Floatz logo

Nivolumab

Hematopoietic And Lymphoid Cell Neoplasm

Explore 115 assets in Hematopoietic And Lymphoid Cell Neoplasm →
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04781855CT.gov
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
—Withdrawn———
NCT04730349CT.gov
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
—Terminated———
NCT04500548CT.gov
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
—Withdrawn———
NCT03816345CT.gov
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
—Recruiting———
NCT03283046CT.gov
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
—Withdrawn———
NCT02465060CT.gov
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematopoietic And Lymphoid Cell Neoplasm

AssetSponsorPhaseRating
Nivolumab (this asset)M.D. Anderson Cancer CenterP2BB · 65
NivestimSt. Jude Children's Research HospitalP2BB
PegloticaseM.D. Anderson Cancer CenterP4BB
RasburicaseM.D. Anderson Cancer CenterP4BB
Cyclosporin AChildren's Oncology GroupP3BB
HydromorphonM.D. Anderson Cancer CenterP4BB
PrednisoneM.D. Anderson Cancer CenterP2BB
TacrolimusFred Hutchinson Cancer CenterP2BB
FludarabineNational Cancer Institute (NCI)P3BB

+42 more in the Hematopoietic And Lymphoid Cell Neoplasm cohort

Other indications for Nivolumab

IndicationSponsorPhaseRating
Renal Carcinoma—P4BBB · 72
Metastatic Melanoma—P4BB · 70
Non-Small Cell Lung Carcinoma—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nivolumab in Hematopoietic And Lymphoid Cell Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nivolumab-hematopoietic-and-lymphoid-cell-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →